

Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C

April 24 2015

A new study presented today at The International Liver Congress 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; primary endpoint), of 93% and 95% in patients chronically infected with hepatitis C virus (HCV) genotypes 4 or 5, respectively.

In the study, LDV/SOF was administered in a once-daily, fixed-dose combination tablet for 12 weeks to treatment-naïve and treatment-experienced [patients](#) with or without cirrhosis. A total of 85 patients were enrolled in the study: 44 patients had GT-4 and 41 patients had GT5 chronic HCV infection. SVR12 rates were similar across all patient types.

HCV GT-4 is estimated to account for 8% to 13% and GT-5 for about 1% of all chronic HCV infections globally. Clinical studies evaluating the treatment outcome with new direct-acting antiviral agents in GT-4 and especially GT-5 HCV infection have been limited, to date.

More information: LEDIPASVIR/SOFOSBUVIR TREATMENT RESULTS IN HIGH SVR RATES IN PATIENTS WITH CHRONIC GENOTYPE 4 AND 5 HCV INFECTION, The International Liver Congress 2015.

Provided by European Association for the Study of the Liver

Citation: Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C (2015, April 24) retrieved 2 May 2024 from <https://medicalxpress.com/news/2015-04-ledipasvir-sofosbuvir-combination-effective-subset-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.